Christopher Liu
Stock Analyst at Leerink Partners
(2.44)
# 2,372
Out of 4,876 analysts
5
Total ratings
50%
Success rate
19.95%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Christopher Liu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RLAY Relay Therapeutics | Maintains: Outperform | $19 → $18 | $3.30 | +445.45% | 1 | Dec 4, 2024 | |
| IDYA IDEAYA Biosciences | Downgrades: Market Perform | $41 → $27 | $21.37 | +26.35% | 2 | Nov 5, 2024 | |
| NUVL Nuvalent | Initiates: Market Perform | $42 | $79.68 | -47.29% | 1 | Aug 8, 2023 | |
| EXEL Exelixis | Initiates: Market Perform | $18 | $43.67 | -58.78% | 1 | Aug 8, 2023 |
Relay Therapeutics
Dec 4, 2024
Maintains: Outperform
Price Target: $19 → $18
Current: $3.30
Upside: +445.45%
IDEAYA Biosciences
Nov 5, 2024
Downgrades: Market Perform
Price Target: $41 → $27
Current: $21.37
Upside: +26.35%
Nuvalent
Aug 8, 2023
Initiates: Market Perform
Price Target: $42
Current: $79.68
Upside: -47.29%
Exelixis
Aug 8, 2023
Initiates: Market Perform
Price Target: $18
Current: $43.67
Upside: -58.78%